CLEAR: the intraventricular haemorrhage thrombolysis trial. by Akhtar, Anjum & Kamal, Ayeesha Kamran
eCommons@AKU
Department of Medicine Department of Medicine
July 2013
CLEAR: the intraventricular haemorrhage
thrombolysis trial.
Anjum Akhtar
Aga Khan University
Ayeesha Kamran Kamal
Agha Khan University, ayeesha.kamal@aku.edu
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Neurology Commons
Recommended Citation
Akhtar, A., Kamal, A. (2013). CLEAR: the intraventricular haemorrhage thrombolysis trial.. JPMA. The Journal of the Pakistan Medical
Association, 63(7), 928-928.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/357
Availability of a well-equipped stroke unit, intravenous
thrombolysis and expert stroke teams has dramatically
improved stroke outcomes for acute ischaemic stroke.
Stroke from intracerebral haemorrhage (ICH), however,
still carries a high mortality rate. ICH related to high blood
pressure accounts for 10 to 20% of the stroke worldwide
with a mortality of 50 to 80% in those with intraventricular
extension due to associated obstructive hydrocephalous
and perilesional oedema. Any strategy to overcome this
obstacle will help to minimise the future morbidity.
What is the study under consideration?
CLEAR is a phase III clinical trial testing low dose
thrombolytic therapy in patients presenting with ICH with
intraventricular  extension within 4 hours. The sample
constituted 48 patients enrolled  from 14 centres. Adults
aged 18 to 75 years with supratentorial ICH of less than 30
ml with massive IV extension and an external ventricular
drain  already in place for treatment of obstructive
hydrocephalous were selected for this trial.
What was the study design?
The patients were randomised to treatment with 3mg
intraventricular rtPA through external ventricular drain or
placebo (3ml of normal saline). Medicine or placebo were
given 12 hourly and continued till they found the
evidence of resolution of clot which was 7.5 days for rtPA
and 12 days for placebo. Clot resolution was measured
with daily CT scan of the brain. 
What were the results? 
Rate of clot resolution was significantly higher in the rtPA
treated group which was 18%/day versus 8%/day in the
placebo treated patients. This was statistically significant.
Why is this study important? 
We have had very little option in improving the outcome
of the patients with ICH up till now. Intraventricular
thrombolysis may prove to be beneficial in ICH. Though
several other small clinical trials have also shown the
significant benefit of low dose thrombolysis using
intraventricular catheter, but further data is needed to
support this evidence.
What this means for Pakistan?
We should be on the alert for future data on this
therapeutic option, since our outcomes may be even
better than reported given the young, frequent ICH with
intraventricular extension in our region. 
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